Compare Ascendis Pharma A/S (ASND) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs JPMorgan Ultra Short Income ETF — how do they compare? Ascendis Pharma A/S trades at $254.5 (market cap $16.67B), while JPMorgan Ultra Short Income ETF trades at $50.45. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals.
| ASND | JPST | |
|---|---|---|
Market Cap | $16.67B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $277.18 | $50.78 |
52-Week Low | $189.74 | $50.40 |
Enterprise Value | $17.04B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →
